Molina’s Cost Curve Concealment Triggers Shareholder Lawsuit

Molina Healthcare promised steady growth and solid earnings. Executives said medical costs were under control and 2025 was on track. Investors expected stability.

But behind the curtain, something very different was happening.

In February 2025, the company reaffirmed strong guidance. In April, they repeated the same message. Then July hit. On July 7, Molina admitted medical costs were rising fast and cut earnings guidance by about 10%. The stock slipped.

Just 16 days later, on July 23, the truth landed harder. Molina slashed guidance again, this time to no less than $19 a share. They blamed accelerating medical costs and higher use of behavioral health, pharmacy, and inpatient care. The stock collapsed nearly 17% in a single day.

Investors were stunned. Confidence evaporated.

Now, more shareholders are joining the lawsuit.